An article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.
According to Professor Antonio Fea from the University of Turin, who authored the article, the suprachoroidal space presents a number of distinctive advantages: it can be easily accessed ab interno which spares the conjunctiva, it enables a significant IOP drop, and the surgical technique has a short learning curve.
A possible reason why previous attempts to utilise the suprachoroidal space in the treatment of glaucoma have failed may be that the devices were made of unsuitable materials
Professor Fea
According to Fea, MINIject’s anti-fibrotic, biocompatible and bio-integrating material may therefore help overcome some of the drawbacks of previous devices that attempted to use the suprachoroidal route. Its softness, flexibility and minimal protrusion into the anterior chamber of the eye may also help minimise endothelial cell damage.
To view the full article: https://europe.ophthalmologytimes.com/view/a-new-route-to-reducing-iop
